Recall rebound boosts J&J quarterly results

Share this article:

Johnson & Johnson ended the first quarter with $17.5 billion in sales, an 8.5% increase over the same period last year.

US sales were $8 billion, up just over 11% compared to the same period last year, and international sales were $9.5 billion, up just over 6%. Consumer products – which includes baby care, oral care, and OTC medications, among other categories – saw sales rise 2% over the same period last year, to $3.7 billion, up from $3.6 billion. Part of this growth comes from getting products back on shelves after a series of recalls.

Pharmaceutical sales were up around 15% in the US and 6% internationally. Notable growth spots included biologic Stelara, with sales rising 57% overall, compared to the same period last year, and 75% in the US, to $226 million, and to $120 million internationally. Sales of schizophrenia medication Invega rose 64% in the US, to $164 million for the quarter, and 98% internationally, to $120 million. Sales of prostate cancer drug Zytiga sales rose 72% overall, to $344 million, with  $161 million in US sales and $183 million internationally.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.